Valuation: Castle Biosciences, Inc.

Market Cap 731M 639M 587M 548M 1.04B 69.63B 1.05B 7.05B 2.74B 34.22B 2.74B 2.69B 118B P/E 2026 *
-17.2x
P/E 2027 * -25.8x
Enterprise Value 731M 639M 587M 548M 1.04B 69.63B 1.05B 7.05B 2.74B 34.22B 2.74B 2.69B 118B EV / Sales 2026 *
2.07x
EV / Sales 2027 * 1.86x
Free-Float
97.27%
Yield 2026 *
-
Yield 2027 * -
1 day-2.43%
1 week-0.78%
Current month+1.09%
1 month+18.24%
3 months-2.94%
6 months-37.44%
Current year-38.02%
1 week 23.36
Extreme 23.36
24.98
1 month 19.86
Extreme 19.855
24.98
Current year 17.72
Extreme 17.722
44.28
1 year 14.59
Extreme 14.59
44.28
3 years 12.07
Extreme 12.07
44.28
5 years 9.26
Extreme 9.2601
78.58
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 01/09/2007
Director of Finance/CFO 56 01/12/2017
Chief Tech/Sci/R&D Officer - 01/07/2021
Director TitleAgeSince
Director/Board Member 64 01/09/2007
Chairman 64 01/09/2014
Director/Board Member 70 06/12/2018
Date Insider Type Main position Quantity % Market Cap.
06-16Sell

Chief Operating Officer

-8,587 0.0283%
06-15Fiscal year

Founder

5,272 0.0174%
06-01Fiscal year

Founder

22,264 0.0734%
Change 5-day change 1-year change 3-year change Capi.($)
-2.43%-0.78%+18.77%+77.93% 731M
-1.63%+12.57%+232.63%+375.33% 22.27B
-1.27%-2.18%-41.43%-25.52% 9.4B
+0.85%+0.08%+36.65%+31.18% 7.15B
-2.40%-1.08%-31.05% - 5.17B
+0.23%+4.51%-19.64%-25.14% 5.13B
-0.10%+6.15%+199.85%-31.25% 4.95B
+0.61%+2.14%-22.74%-25.43% 4.23B
-1.07%-0.09%+81.53%+87.15% 4.1B
+2.89%+8.01%-17.54%-41.07% 2.61B
Average -0.43%+3.68%+43.70%+47.02% 6.58B
Weighted average by Cap. -0.76%+6.78%+91.07%+136.32%

Financials

2026 *2027 *
Net sales 353M 308M 283M 264M 501M 33.58B 509M 3.4B 1.32B 16.51B 1.32B 1.3B 56.88B 393M 344M 316M 295M 559M 37.46B 567M 3.79B 1.48B 18.42B 1.48B 1.45B 63.46B
Net income -43.46M -38M -34.92M -32.55M -61.73M -4.14B -62.67M -419M -163M -2.03B -163M -160M -7.01B -26.06M -22.78M -20.93M -19.51M -37.01M -2.48B -37.57M -251M -97.7M -1.22B -97.81M -95.71M -4.2B
Net Debt - -
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
942
Date Price Change Volume
02/07/26 $24.11 -2.43% 175,503
01/07/26 $24.71 +3.61% 318,282
30/06/26 $23.85 -1.93% 336,710
29/06/26 $24.32 +0.08% 324,265
26/06/26 $24.30 +6.07% 1,043,847
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.11USD
Average target price
43.56USD
Spread / Average Target
+80.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSTL Stock